Together, these results indicate that TRPV1 is indispensable for dry eye-induced cold allodynia, and pharmacological suppression of TRPV1 is a promising therapeutic strategy for dry eye-associated cold allodynia. This evidence concerns the gene TRPV1 and dry eye syndrome.